HESI Emerging Issues Committee
CT-TRACS sub-committee: Cell Therapy - TRAcking, Circulation, & Safety

90-minute Joint Session at ISCT 2017: Saturday May 6\textsuperscript{th}, 2017. 15:00 – 16:30
http://isct2017.com

THEME: “Identifying and Optimizing Emerging Technologies to Evaluate Cell Therapy Safety, Mode of Action and Efficacy”

AIMS:
1. The sub-committee aims to bring awareness on how the application of existing cell tracking technologies, methods, and best practices can benefit the clinical translation of cell therapies.

2. To promote the dialogue with the international community and discuss opportunities to address the challenges facing the translation of cell therapies into the clinic. CT-TRACS is an international and multi-disciplinary team of experts with interest in sharing their knowledge, common challenges and seek consensus on finding harmonized solutions.


SESSION PROGRAM:

Session Chair: Dr. William Shingleton (GE Healthcare, CT-TRACS co-chair)

1. Introduction: HESI CT-TRACS structure, mission, goals and collaborations (5 min) - Chair

2. Current developments: (presenters from CT-TRACS and two guest speakers, 10 min each)
   a. Tracking cells after administration/biodistribution:
      i. Imaging modalities and probes (Dr. Brooke Helfer, Celsense, CT-TRACS sub-group co-leader)
      ii. Preclinical and clinical biodistribution study in cell-based therapeutic product development (Dr. Nobuhiro Umeda, Astellas)
   b. Tumorigenicity assessment:
      i. Tumorigenicity Assessment of Human Cell-Based Therapeutic Products (Dr. Yoji Sato, Head of the Division of Cell Based Therapeutic Products, NIH Japan).
      ii. Tumorigenicity Evaluations of AST-OPC1: Oligodendrocyte Progenitor Cells for the Treatment of Spinal Cord Injury (case-study) – Dr. Jane Lebkowski, President of R&D and Chief Scientific Officer, Asterias

3. Panel Discussion – panelists will include the presenters from part 2. Session Chair will facilitate the discussion. Focus on gaps and needs in an interactive discussion with the audience. Seeking feedback from therapy developers and regulators (30 minutes).

For questions, please contact Dr. Lucilia Mouriès, HESI Scientific Program Manager: lmouries@hesiglobal.org